FGFR-IN-28

FGFR-IN-28 (F1-7) dose-dependently inhibits the kinase activity of recombinant FGFR1, FGFR2, FGFR3, and FGFR4 proteins with IC₅₀ values of 10, 21, 50, and 4.4 nmol/L, respectively^[1].
FGFR-IN-28 (48 h) dose-dependently reduces the viability of HCT-116, RKO, and SW620 human colon cancer cells with IC₅₀ values of 1.271 μM, 2.046 μM, and 1.433 μM^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently inhibits the phosphorylation of FGFR, AKT, and MAPK in HCT-116, RKO, and SW620 human colon cancer cells following 12 h of treatment, without altering total FGFR protein levels^[1].
FGFR-IN-28 (2.0 μM; 12 h) alters the transcriptome of HCT-116 human colon cancer cells, significantly enriching genes in the MAPK signaling, apoptosis, and ferroptosis pathways^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently inhibits colony formation in HCT-116, RKO, and SW620 human colon cancer cells^[1].
FGFR-IN-28 (1.0-4.0 μM; 48 h) dose-dependently induces apoptosis in HCT-116, RKO, and SW620 human colon cancer cells^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently modulates apoptosis-related protein expression in HCT-116, RKO, and SW620 human colon cancer cellst, increasing cleaved-PARP and Bax while decreasing Bcl-2^[1].
FGFR-IN-28 (4.0 μM) induces cell death in HCT-116 human colon cancer cells via both apoptosis and ferroptosis after 48 h of treatment, as shown by reduced cell death when co-treated with Z-VAD (HY-164388) or ferrostatin-1 (HY-100579), respectively^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently increases expression of the DNA damage biomarker γ-H2AX in HCT-116 and RKO human colon cancer cells after 24 h of treatment^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently induces DNA fragmentation, measured via increased comet tail formation, in HCT-116, RKO, and SW620 human colon cancer cells after 24 h of treatment^[1].
FGFR-IN-28 (2.0-4.0 μM; 24 h) dose-dependently reduces DNA synthesis and cell proliferation in HCT-116 human colon cancer cells, as measured by decreased EdU incorporation following 24 h of treatment^[1].
FGFR-IN-28 (1.0-4.0 μM; 24 h) dose-dependently induces G2/M cell cycle arrest in HCT-116, RKO, and SW620 human colon cancer cells after 24 h of treatment, accompanied by reduced expression of CyclinB1, MDM2, and CDK1^[1].
FGFR-IN-28 (1.0-4.0 μM; pretreatment duration not specified; 1 h adhesion incubation) dose-dependently inhibits the adhesion ability of HCT-116, RKO, and SW620 human colon cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.